- 1.11 mg - olopatadine hydrochloride equivalent to 1 mg olopatadine.
- 0.01% - benzalkonium chloride.
- dibasic sodium phosphate;
- sodium chloride;
- hydrochloric acid/sodium hydroxide;
- purified water.
Patanol eye drops 0.1% are indicated for the treatment of the signs and symptoms of allergic conjunctivitis.
Patanol eye drops 0.1% are contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any
components of Patanol eye drops.
Patanol eye drops 0.1% are for topical use only and not for injection or oral use.
Patanol eye drop was found not to be teratogenic in rats and rabbits.
However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day,
or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however,
no adequate and well controlled studies in pregnant women. Because animal studies are not always
predictive of human responses, Patanol eye drop should be used in pregnant women only if the potential benefit to
the mother justifies the potential risk to the embryo or fetus.
Patanol eye drop has been identified in the milk of nursing rats following oral administration.
Patanol eye drop is not known whether topical ocular administration could result in sufficient systemic absorption to produce
detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Patanol eye drops
0.1% are administered to a nursing mother.
Headaches have been reported at an incidence of 7%.
The following adverse experiences have been reported in less than 5% of patients:
- Taste perversion;
- Lid edema;
- Foreign body sensation;
- Dry eye;
- Cold syndrome;
- Burning or stinging;
- Blurred vision;
Patanol eye drop recommended dose is 1 drop in each affected eye two times per day at an interval of 6 to 8 hours.
Patanol eye drop 0.1% is supplied as follows: 5 mL in plastic dropper bottles.